<DOC>
	<DOCNO>NCT00045006</DOCNO>
	<brief_summary>RATIONALE : Suberoylanilide hydroxamic acid may stop growth cancer cell block enzymes necessary cancer cell growth . PURPOSE : Phase I trial study effectiveness suberoylanilide hydroxamic acid treat patient advanced cancer .</brief_summary>
	<brief_title>Suberoylanilide Hydroxamic Acid Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose suberoylanilide hydroxamic acid patient advance solid tumor hematologic malignancy . - Evaluate pharmacokinetic profile drug patient . - Determine effect drug absorption fast non-fasting state patient . - Determine anti-tumor effect drug patient . - Correlate clinical outcome histone acetylation circulate mononuclear cell tumor biopsy sample patient treated drug . OUTLINE : This dose-escalation study . Patients stratify accord disease ( solid tumor v multiple myeloma lymphoma v leukemia myelodysplastic syndrome ) . The initial 15-20 patient ( solid tumor multiple myeloma lymphoma stratum ) receive suberoylanilide hydroxamic acid ( SAHA ) IV 2 hour day 1 week 0 orally twice daily begin day 1 week 1 . All remain patient receive oral SAHA twice daily begin day 1 week 1 . Courses repeat every 4 week 1 year absence disease progression unacceptable toxicity . In stratum , cohorts 3-6 patient receive escalate dos SAHA maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Patients follow monthly resolution adverse event . PROJECTED ACCRUAL : A maximum 114 patient ( 42 solid tumor , 36 lymphoma multiple myeloma , 36 leukemia myelodysplastic syndrome ) accrue study within 1 year .</detailed_description>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow diagnosis : Histologically confirm advanced primary metastatic solid tumor , include , limited , follow : Androgenindependent prostate cancer Breast cancer Ovarian cancer Head neck cancer Nonsmall cell lung cancer Bladder cancer Kidney cancer Diagnosis lymphoma , multiple myeloma , leukemia , myelodysplastic syndrome ( MDS ) , include , limited , follow : Intermediategrade follicular nonHodgkin 's lymphoma Hodgkin 's lymphoma Patients lymphoma multiple myeloma must ineligible peripheral blood stem cell transplantation For patient solid tumor ( except prostate cancer ) : Disease progression base development new lesion increase preexist lesion Biochemical marker increase must sole criterion disease progression For prostate cancer patient : Disease progression base rise prostatespecific antigen ( PSA ) value , transaxial imaging , radionuclide scan Increase diseaserelated symptom must sole manifestation progression Patients receive antiandrogen part firstline hormonal therapy must show disease progression antiandrogen prior study Biochemical progression ( least 25 % increase range value ) define 1 following : Rising PSA document least 3 consecutive measurement obtain least 1 week apart Rising PSA document least 2 consecutive measurement obtain 1 month apart PSA least 4 ng/mL Testosterone great 50 ng/mL If prior orchiectomy , must maintain castrate level testosterone Disease must refractory standard therapy curative therapy exist No active CNS epidural tumor Hormone receptor status : Not specify NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age 18 Sex Male female Menopausal status Not specify Performance status Karnofsky 70100 % Life expectancy Not specify Hematopoietic WBC least 3,500/mm^3 Platelet count least 100,000/mm^3 ( patient solid tumor ) Platelet count great 25,000/mm^3 ( patient hematologic malignancy ) Absolute neutrophil count least 500/mm^3 ( patient hematologic malignancy ) Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 3 time ULN PT great 15 second Renal Creatinine great 2.0 mg/dL Cardiovascular No New York Heart Association class III IV heart disease Pulmonary No severe debilitate pulmonary disease Other No infection require IV antibiotic No severe medical problem would preclude study participation Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy At least 4 week since prior chemotherapy Endocrine therapy See Disease Characteristics At least 4 week since prior ketoconazole At least 2 week since prior steroid patient lymphoma Concurrent gonadotropinreleasing hormone analog diethylstilbestrol maintain castrate level testosterone allow prostate cancer patient No concurrent ketoconazole Radiotherapy At least 4 week since prior radiotherapy No concurrent radiotherapy sole measurable lesion Surgery See Disease Characteristics No concurrent surgery Other Recovered prior therapy At least 4 week since prior palliative therapy solid tumor patient progressive metastatic disease ( present ) At least 4 week since prior investigational anticancer therapeutic drug At least 2 week since prior conventional cytotoxic therapy patient leukemia MDS At least 4 week since prior investigational therapy patient leukemia MDS No concurrent investigational drug No concurrent anticancer agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2003</verification_date>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>borderline ovarian surface epithelial-stromal tumor</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>ovarian stromal cancer</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III ovarian germ cell tumor</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>stage III oropharyngeal cancer</keyword>
	<keyword>stage IV oropharyngeal cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
	<keyword>stage III salivary gland cancer</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent verrucous carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage III verrucous carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV verrucous carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent lymphoepithelioma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III lymphoepithelioma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV lymphoepithelioma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent lymphoepithelioma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III lymphoepithelioma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV lymphoepithelioma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage III esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>stage III invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>stage III midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>stage III squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent basal cell carcinoma lip</keyword>
	<keyword>stage III basal cell carcinoma lip</keyword>
	<keyword>stage IV basal cell carcinoma lip</keyword>
	<keyword>recurrent mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage III mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage IV mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>recurrent adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage III adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage IV adenoid cystic carcinoma oral cavity</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
	<keyword>stage III verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>male breast cancer</keyword>
</DOC>